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Restricted VH/VL usage and limited mutations
in gluten-speciﬁc IgA of coeliac disease lesion
plasma cells
Øyvind Steinsbø1, Carole J. Henry Dunand2, Min Huang2, Luka Mesin1, Marlene Salgado-Ferrer2,
Knut E.A. Lundin1,3, Jørgen Jahnsen4, Patrick C. Wilson2 & Ludvig M. Sollid1
Coeliac disease (CD), an enteropathy caused by cereal gluten ingestion, is characterized by
CD4þ T cells recognizing deamidated gluten and by antibodies reactive to gluten or the
self-antigen transglutaminase 2 (TG2). TG2-speciﬁc immunoglobulin A (IgA) of plasma cells
(PCs) from CD lesions have limited somatic hypermutation (SHM). Here we report that
gluten-speciﬁc IgA of lesion-resident PCs share this feature. Monoclonal antibodies were
expression cloned from single PCs of patients either isolated from cultures with reactivity to
complex deamidated gluten antigen or by sorting with gluten peptide tetramers. Typically, the
antibodies bind gluten peptides related to T-cell epitopes and many have higher reactivity to
deamidated peptides. There is restricted VH and VL combination and usage among the
antibodies. Limited SHM suggests that a common factor governs the mutation level in PCs
producing TG2- and gluten-speciﬁc IgA. The antibodies have potential use for diagnosis of
CD and for detection of gluten.
DOI: 10.1038/ncomms5041 OPEN
1 Centre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital-Rikshospitalet, 0372 Oslo, Norway.
2 Department of Medicine, Section of Rheumatology, Committee on Immunology, The Knapp Center for Lupus and Immunology Research, University of
Chicago, Chicago, Illinois 60637, USA. 3 Department of Gastroenterology, Oslo University Hospital-Rikshospitalet, 0372 Oslo, Norway. 4Division of
Medicine, Department of Gastroenterology, Akershus University Hospital, 1478 Lørenskog, Norway. Correspondence and requests for materials should be
addressed to L.M.S. (email: l.m.sollid@medisin.uio.no).
NATURE COMMUNICATIONS | 5:4041 | DOI: 10.1038/ncomms5041 | www.nature.com/naturecommunications 1
& 2014 Macmillan Publishers Limited. All rights reserved.
C
oeliac disease (CD) is a chronic T-cell-mediated inﬂam-
matory enteropathy resulting from an inappropriate
immune response to dietary gluten proteins (consisting
of gliadin and glutenin components) of wheat, barley and rye.
The disorder is controlled by gluten, as elimination of gluten from
the diet leads to disease remission and resolution of the small
intestinal disease lesion, whereas gluten provocation leads to
reoccurrence of disease and pathology1. Distinct features of the
disease are cell-mediated immunity to gluten and highly speciﬁc
humoral responses to both gluten and the self-antigen
transglutaminase 2 (TG2)2. Leukocyte inﬁltrations in the CD
lesion reﬂect these immunological features; gluten-reactive
CD4þ T cells recognizing deamidated gluten peptides in the
context of the disease associated HLA-DQ2 and HLA-DQ8
molecules3 as well as plasma cells (PCs) secreting gluten-speciﬁc
or TG2-speciﬁc immunoglobulin A (IgA) and IgM antibodies are
found in the intestinal lamina propria of CD patients4,5.
Antibodies to gluten and TG2 have become increasingly
important for the diagnostic workup of CD6,7. In children,
histological assessment of biopsies in many cases is no longer
considered mandatory due to high diagnostic accuracy of
serologic assays7. A similar diagnostic pathway has also been
suggested for adults8. Serologic testing is informative when
subjects are consuming a gluten-containing diet. Antibodies both
to gluten9 and TG2 (ref. 10) disappear within months after
introduction of a gluten-free diet. The parallel ﬂuctuation of
antibodies to gluten and TG2 in serum and at the plasma cell level
in the intestine11 in response to dietary gluten suggests that the
production of these antibodies is regulated in a coordinated way.
The epitopes recognized by gluten-reactive CD4þ T cells of CD
patients are well characterized. Typically, the T-cell epitopes harbour
glutamate residues, which have been introduced by TG2-mediated
deamidation of certain glutamine residues12. Less is known about
gluten B-cell epitopes. Some epitopes have been characterized by
studying polyclonal serum antibody reactivity to synthetic peptides
of gliadin proteins13 and by bacterial cell-displayed peptide
libraries14. Deamidation is also relevant for the B-cell epitopes,
and serum antibody reactivity is higher to deamidated than the
corresponding native (non-deamidated) peptides13,15.
Gliadin B-cell epitopes appear to be situated in proximity
and/or to overlap with gliadin T-cell epitopes13,15. Furthermore,
serum IgA antibodies to TG2, and likely also to deamidated
gliadin, only occur in subjects who are HLA-DQ2 or HLA-DQ8
(ref. 16). The HLA dependence of the antibody production and
the colocalization of T-cell epitopes and B-cell epitopes suggest
that the antibody response to gluten in CD is T cell dependent.
Similarly, the HLA dependence of TG2 antibodies suggests T-cell
involvement for their formation. Thus, it was surprising that the
TG2 IgA expression cloned from CD lesions displayed limited
somatic hypermutation (SHM)5.
In order to shed further light on the humoral immunity in CD,
we have characterized the gluten-speciﬁc IgA antibody response
of CD that happens in parallel to the autoantibody response to
TG2. We have pursued two complementary approaches to
identify gliadin-speciﬁc IgAþ PCs from small intestinal biopsies
of subjects with untreated CD (UCD). In one, we isolated gliadin-
speciﬁc PCs by culturing single PCs and screening the culture
supernatants for IgA reactivity to complex gliadin antigen in an
epitope unbiased fashion. In another, we analysed and sorted
single IgAþ PCs with complexes of ﬂuorescent streptavidin
and biotinylated synthetic gliadin peptides by ﬂow cytometry.
We generated a panel of human monoclonal antibodies (hmAbs)
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Figure 1 | Survival of intestinal PCs in culture. (a) Concentration of IgA in supernatants after 0, 1, 2, 3 and 4 weeks culture of SCSs (4-5000 cells ml 1)
grown with (Fþ ) or without ﬁbroblasts (F ). (b) Concentration of IgA after 0 and 2 days in supernatants from cultures of ﬁbroblasts and PCs when PCs
were added either as isolated IgAþ PCs (IgAþ PCs) or as part of SCSs (80-100 IgAþ PCs ml 1). IgA was detectable only in cultures of PCs as part of
SCSs. The bars represents mean values of three separate culture wells and error bars represent s.e.m. (ND denotes non-detectable). (c) Representative
ﬂow cytometry plots of SCSs after 4 weeks of co-culture with ﬁbroblasts. Viable PCs identiﬁed as large (left), viable CD27þCD3CD14 (middle) cells as
indicated by gating strategy. The PC population divides into IgMþ and IgM PCs, where the IgM are mainly IgAþ PCs (right).
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from single PCs speciﬁc for gliadin and report that these
antibodies have restricted VH and VL usage and limited SHM.
These results give insights into the mechanisms of the production
of gluten-speciﬁc and TG2-speciﬁc IgA antibodies in CD and
suggest that the limited somatic mutation in both populations is
controlled by similar factor(s).
Results
Intestinal PCs secreting IgA reactive with gliadin. In vitro
culture was a critical step for isolation of PCs producing anti-
bodies reactive with heat/acid-treated chymotrypsin-digested
gliadin (hereafter termed CT-gliadin for short). Three conditions
of PC cultures were compared. Single-cell suspensions (SCSs)
from intestinal biopsies were generated, and PCs were cultured
either as SCSs, as SCSs in co-culture with human intestinal
ﬁbroblasts or as PCs isolated by ﬂow cytometry in co-culture with
ﬁbroblasts. The concentration of IgA in supernatants of cultures
with SCSs together with ﬁbroblasts increased with a constant rate
over at least 4 weeks (Fig. 1a), suggesting that the majority of
PCs survived in these cultures. We did not observe any increase
of IgA in supernatants of cultures of SCSs alone (Fig. 1a) or ﬂow
cytometry sorted PCs cultured with ﬁbroblasts (Fig. 1b). In co-
cultures of SCSs and ﬁbroblasts, we observed that intestinal PCs
survived for weeks, and viable CD19þCD27þ PCs were detected
by ﬂow cytometry after 4 weeks of culture (Fig. 1c). PCs did not
proliferate in these cultures, as tested in a BrdU incorporation
assay. Based on these ﬁndings, the system of co-culturing SCSs
and ﬁbroblasts was selected for further experiments.
We aimed at analysing the speciﬁcity of antibodies produced
at a single PC level. Based on the frequency of IgAþ PCs in
SCSs that was determined by ﬂow cytometry (mean 3.3%, range
1.0–5.3%, n¼ 16) (Supplementary Fig. 1a,b), we seeded 10–20
cells per well to obtain cultures with less than one IgAþ PC per
well. Supernatants of single wells were screened for IgA reactivity
to CT-gliadin and TG2. Supernatants containing IgA reactive
to TG2 were three to four times more frequent than IgA
reactive to CT-gliadin in cultures from subjects with UCD
(Fig. 2a,b). Importantly, IgA reactivity to TG2 and CT-gliadin
was not detected in supernatants from cultures of non-coeliac
controls (Fig. 2c) or supernatants of cultures containing only
ﬁbroblasts (Fig. 2d). Thus, PCs secreting IgA reactive to CT-
gliadin are present in small intestinal biopsies of subjects with
UCD and are less frequent than PCs secreting TG2-reactive IgA.
Next, we wanted to clone and express the antibody genes of PCs
from cultures in which we detected IgA reactivity to CT-gliadin in
the supernatant. In the SCSs, the large PCs hugely outnumbered
small resting B cells (Supplementary Fig. 1c,d). Conceivably, if one
well of SCSs contained just one IgAþ PC, there was a high
probability that this was the only cell expressing the IgA-encoding
genes in that well. Where ELISA results suggested gliadin-speciﬁc
PCs to be present (Fig. 2a), the cells were split into four PCR wells
and processed individually to increase the likelihood of having only
one PC in each well. Cells were then washed in phosphate-buffered
saline (PBS) before snap freezing in DNase-containing buffer and
subjected to expression cloning of antibodies in a human IgG1
format as previously described17. hmAbs were successfully
produced from more than half of cultures processed. Of a total
of 19 hmAbs produced, nine were reactive to CT-gliadin (Fig. 3a).
These were tested for reactivity to bovine serum albumin (BSA)
and CpG, of which one was found reactive to BSA (Fig. 3b). Thus,
eight hmAbs were considered to be gliadin speciﬁc and included in
further assays.
Intestinal IgAþ PCs stained with gliadin peptides in ﬂow
cytometry. We had previously succeeded in visualizing antigen-
speciﬁc IgAþ PCs by staining with biotinylated antigen bound to
ﬂuorescent streptavidin taking advantage of surface IgA and IgM
expression of gut PCs5,18. We used the same strategy
to identify gliadin-speciﬁc IgAþ PCs by ﬂow cytometry, using
ﬂuorescent streptavidin to form tetramer complexes with
biotinylated synthetic peptides. Two different gliadin peptides
with sequences targeted by serum IgA antibodies of CD patients,
biotin-(GSGSGS)-PLQPEQPFP13 and biotin-(PEG)-LQLQPFP
QPELPYPQPELPYPQPELPYPQPQPF19, were used as antigen.
The two peptides represent sequences of gliadin with Q to E
transitions in positions targeted by TG2 (ref. 12). Importantly,
both peptides are reported to bind antibodies from UCD patients,
primarily in their deamidated versions15. PLQPEQPFP in
particular has demonstrated high sensitivity and speciﬁcity for
CD in serologic assays20. This approach using synthetic peptides,
introduced a restricted selection of gliadin-speciﬁc PCs compared
with screening culture supernatants for IgA reactivity against
CT-gliadin.
In ﬂow cytometry, the mean percentage of IgAþ PCs stained
with the PLQPEQPFP peptide tetramers was 1.0% (range
0.3–2.6%, n¼ 10) of total IgAþ PCs in SCSs generated from
biopsies taken from UCD patients (Fig. 4a,b). In comparison, the
mean percentage in non-CD disease controls was 0.2% (range
0–0.3%) (Fig. 4a,b). For IgAþ PCs stained with the deamidated
33-mer peptide tetramers, the mean percentage was 0.5% (range
0.4–0.9%, n¼ 6) for subjects with UCD and 0.1% in controls
(range 0–0.3%, n¼ 4). Background levels were deﬁned by staining
IgAþ PCs with ﬂuorescent streptavidin alone (mean 0.3%, range
0.2–0.4%, n¼ 4) (Fig. 4b).
Importantly, IgAþ PCs stained with synthetic gliadin peptides
and TG2 appeared as two separate populations in ﬂow cytometry
whereas double-positive cells were not detected (Fig. 4c). Also, the
populations visualized with TG2 were larger than the populations
stained with both the PLQPEQPFP and the deamidated 33-mer
peptides (Fig. 4d). These ﬁndings are consistent with the ratio of
the frequencies of IgAþ PCs reactive with TG2 versus those
reactive with CT-gliadin observed in culture (Fig. 2b). The
predominance of TG2þ PCs relative to the population stained
with gliadin peptides was greater for the IgAþ PCs than for the
IgMþ PCs (Fig. 4d). Based on these experiments, we conclude
that there are two distinct populations of gliadin-speciﬁc and
TG2-speciﬁc IgAþ PCs in the small intestinal lesions of UCD
patients.
IgAþ PCs stained with ﬂuorescent streptavidin in complex
with either PLQPEQPFP or deamidated 33-mer were isolated as
single cells by ﬂow cytometry for further expression cloning. The
hmAbs obtained were tested for reactivity to the peptide, which
they were originally isolated with. Seventeen of 23 hmAbs from
PCs isolated with the PLQPEQPFP peptide, and 13 of 16 hmAbs
from IgAþ PCs isolated with the deamidated 33-mer peptide
were reactive in ELISA to the peptide originally used in sorting.
This indicates that the staining speciﬁcity of gluten peptide
tetramers was B75–80%.
Afﬁnity of gliadin-speciﬁc hmAbs to deamidated and native
gliadin. The eight hmAbs that originated from in vitro PCs
cultures reactive with CT-gliadin were tested in ELISA against the
two synthetic peptides. Five reacted with PLQPEQPFP (Fig. 3c)
and one reacted with deamidated 33-mer. Hence, six out of
eight hmAbs were reactive to PLQPEQPFP and/or deamidated
33-mer. Since cloning of antibody genes from those cultures is
unbiased with respect to speciﬁc epitope, this result suggests
that the epitopes represented by PLQPEQPFP and the
deamidated 33-mer are recognized by IgA of a signiﬁcant part of
gliadin-speciﬁc PCs.
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The speciﬁcity of all hmAbs reactive to one of the two synthetic
peptides in ELISA was further characterized in AlphaLISA. In
contrast to ELISA, where synthetic peptide was used as a coating
antigen, the AlphaLISA format detected monovalent binding of
hmAbs to soluble biotinylated synthetic peptide. Three of the
hmAbs (UCD1002 1D03, UCD1143 1E01, UCD1130 4A04),
originally from IgAþ PC sorted with tetramers of PLQPEQPFP
and reactive to PLQPEQPFP in ELISA, were not reactive in
AlphaLISA. One of the hmAbs (UCD1130 3B04) from IgAþ PC
sorted with 33-mer and reactive to deamidated 33-mer in ELISA
was not reactive in AlphaLISA. These four antibodies, not
reactive in AlphaLISA, gave the lowest signals in the peptide-
based ELISA and with signals that were lower than to the CT-
gliadin antigen (Supplementary Fig. 2), suggesting that the
synthetic peptides may not represent the complete epitope(s) of
these four antibodies.
Polyreactivity was assessed by using cell lysate as well as a
mixture of Jo-1, TG2, CpG and LPS as competing antigens. In
either case, the binding of hmAbs to the synthetic peptides was
maintained (Fig. 5a). In contrast, the signal was blocked by
CT-gliadin (Fig. 5a). We conclude that the hmAbs reactive to
PLQPEQPFP or deamidated 33-mer are speciﬁc to gliadin and
not polyreactive.
The reactivity of hmAbs to deamidated versus native gliadin
was tested in a competitive AlphaLISA assay. Binding of hmAbs
to biotinylated synthetic deamidated gliadin peptide (either
PLQPEQPFP or the deamidated 33-mer) was tested against the
homologous peptide in either deamidated or native (non-
deamidated) versions. Gliadin-speciﬁc hmAbs divided into two
groups, either only reactive to deamidated gliadin or reactive with
both deamidated and native gliadin (Fig. 5b). None of the hmAbs
had higher reactivity to native than to deamidated gliadin.
Because some of the hmAbs were not reactive to the native
gliadin peptide, this suggests that induction of gliadin-speciﬁc B
cells in vivo likely happens in the presence of deamidated gliadin.
Gliadin-speciﬁc hmAbs bind gliadin peptides with shared
sequences. We observed that some of the hmAbs were reactive
0.8
0.4
0.2
0.0
0.6
O
D4
05
O
D4
05
0.6
0.0
0.2
0.4
0.8
O
D4
05
0.6
0.2
0.4
0.8
0.4
0.2
0.0
0.6
O
D4
05
O
D4
05
0.6
0.0
0.2
0.4
0.8 Ctr 20 cells per well
CT-gliadin IgA
Ctr 20 (left) or 80 (right) cells per well
TG2 IgA
Ctr 80 cells per well
CT-gliadin IgA
Background: only fibroblasts
CT-gliadin IgA
c
d
Ra
tio
 o
f T
G2
 ve
rs
us
 C
T-
gli
ad
in 
0
2
8
4
O
D4
05
0.6
0.0
0.2
0.4
0.8
O
D4
05
0.6
0.0
0.2
0.4
0.8
0.8
0.4
0.2
0.0
0.6
O
D4
05
0.8
0.4
0.2
0.0
0.6
O
D4
05
UCD 80 cells per well
TG2 IgA
UCD 20 cells per well
TG2 IgA
UCD 80 cells per well
CT-gliadin IgA
UCD 20 cells per well
CT-gliadin IgA
a b
Figure 2 | Supernatant reactivity to CT-gliadin and TG2 by ELISA. IgA reactivity to antigen in representative cultures of SCSs from (a) subjects with
UCD. (b) The ratio of culture supernatants with IgA reactivity to TG2 versus CT-gliadin, where the dots represent different subjects with UCD (n¼ 8).
Horizontal bar indicates mean value. (c) IgA reactivity to antigen in one representative of two tested non-CD controls (Ctr). (d) The background level
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with both PLQPEQPFP and the deamidated 33-mer in Alpha-
LISA (Fig. 6a). Eight of the hmAbs originally from IgAþ PC
sorted with tetramers of PLQPEQPFP were reactive to deami-
dated 33-mer (Supplementary Table 1). Of the hmAbs from
IgAþ PC sorted with deamidated 33-mer, eleven were reactive to
PLQPEQPFP (Supplementary Table 1). This suggests that at least
some of the gliadin-speciﬁc PCs secrete antibodies that cross-
react with different gliadin peptides. To test this further, we
investigated whether a few selected synthetic gliadin peptides
could compete with the antibody binding to biotinylated
PLQPEQPFP. We tested the hmAbs (UCD1143 3B02 and
UCD1002 1B06) both of which were reactive with PLQPEQPFP
but not PLQPQQPFP (Supplementary Table 1). For both hmAbs,
the signals were inhibited by peptides containing QPEQ or PEQP.
Peptides without these sequences were non-inhibitory (Fig. 6b).
Thus, the cross-reactivity of hmAbs to different gliadin peptides
appears to be due to sharing of key sequences. Reactivity of many
hmAbs to PLQPEQPFP and deamidated 33-mer, both harbour-
ing the QPEXP (X¼Q, L) and QPFP sequences, is consistent
with this notion.
Binding to PLQPEQPFP of hmAbs is blocked by patient sera.
We wanted to see if binding of gliadin-speciﬁc hmAbs to syn-
thetic gluten peptide was blocked by sera from patients with
active CD. In a preliminary study, sera were incubated with
biotinylated PLQPEQPFP before incubation with AlphaLISA
beads conjugated with two hmAbs UCD1114 1F03 and UCD1143
3B02. Sera from patients with CD blocked the signal, while sera
from control subjects did not (Fig. 7). This suggests that gliadin-
speciﬁc antibodies from serum and IgA of gliadin-speciﬁc PCs in
the lamina propria are speciﬁc to the same gliadin B-cell epitopes.
This is also a promising result as a proof of concept that hmAbs
derived from antigen-speciﬁc human B cells can be used to
establish improved serologic assays.
Repertoire of gliadin-speciﬁc IgAþ PCs. The eight hmAbs from
in vitro-cultured PCs with CT-gliadin were obtained from six
subjects (UCD1050, 1; UCD1130, 1; UCD1065, 2; UCD1186, 2;
UCD1163, 1; UCD1030, 1). The 30 hmAbs derived from single-
sorted PCs using tetramerized synthetic peptides, originated from
ﬁve different subjects (UCD1002, 7; UCD1079, 2; UCD1114, 2;
UCD1130, 16; UCD1143, 3). Control IgAþ PCs, deﬁned as
PLQPEQPFP-negative, 33-mer-negative and TG2-negative
(UCD1130, 55; UCD1143, 54) and TG2-speciﬁc PCs (UCD1030,
3; UCD1114, 4; UCD1010, 2), were isolated by ﬂow cytometry
and their antibody genes were cloned and sequenced. The vari-
able regions of the hmAbs were analysed using tools of the IMGT
webpage (www.imgt.org). Two combinations of VH/VL pairing
were dominant (Fig. 8a); VH3-15/VK4-1 (seven hmAbs from
ﬁve different subjects in total) and VH3-23/VL4-69 (15 hmAbs
from seven different subjects in total). The VH3-23/VL4-69
combination was found in hmAbs from IgAþ PCs isolated with
both CT-gliadin and synthetic peptides. In addition, VH3-23/
VK3-11 was also found in hmAbs generated by both methods.
Together, these three combinations made up B75% of the panel
of gliadin-speciﬁc hmAbs (Fig. 8a, Supplementary Table 1).
We looked for similarity between heavy chain CDR3 sequences of
the VH3-15/VK4-1 as well as the VH3-23/VL4-69 hmAbs. No
obvious similarities could be found with variability in D- and
J-gene segment usage and CDR3-length among the antibodies of
each group (Supplementary Table 1).
VH/VL usage and epitope speciﬁcity. We next compared
VH/VL usage (Supplementary Table 1) with peptide reactivity
pattern characterized in AlphaLISA. All VH3-23/VL4-69 hmAbs
showed reactivity to both native and deamidated gliadin, demon-
strated by inhibiting effect of both the native PLQPQQPFP and the
deamidated PLQPEQPFP. The VH3-15/VK4-1 hmAbs were
speciﬁc to deamidated gliadin, as the native PLQPQQPFP showed
no inhibitory effect on the binding to PLQPEQPFP. VH3-23/
VK3-11hmAbs were the only antibodies with reactivity to dea-
midated 33-mer but not PLQPEQPFP. Two hmAbs had reactivity
to CT-gliadin but neither to PLQPEQPFP nor to deamidated
33-mer. These two antibodies both used VH3-15/VK3-20. Taken
together, this suggested that there is a correlation between VH/VL
usage and epitope speciﬁcity of the gliadin-speciﬁc antibodies.
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Figure 3 | ELISA reactivity of 19 hmAbs expression cloned from IgAþ
PCs in culture. The antigens used for ELISA coating were CT-gliadin and
PLQPEQPFP, and BSA for control as shown in headlines. Values are given as
median and range of triplicates of hmAbs tested. The same hmAbs are
tested for reactivity to all three antigens, and each hmAb is given the same
position in each of the three graphs. The names of the hmAbs are depicted
in 3c. Horizontal bars denote cutoff deﬁned by negative control hmAb (NEG
CTR). (a) Nine of 19 hmAbs were reactive to CT-gliadin. (b) One of nine
hmAbs reactive to CT-gliadin was also reactive to BSA. (c) Five of eight
hmAbs reactive to CT-gliadin but not BSA were also reactive to
PLQPEQPFP.
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SHM within gliadin-speciﬁc IgAþ PCs. The mutation rates in
the hmAbs from PCs secreting IgA reactive with CT-gliadin
(median 8.7, range 3–13, n¼ 8) as well as IgAþ PCs isolated with
synthetic gliadin peptides (median 7.5, range 0–23, n¼ 30) were
lower than in the control PCs (median 15, range 0–37, n¼ 109)
(Fig. 8b). TG2-speciﬁc IgAþ PCs were scarcely mutated as
previously described5 (median 4, range 0–15, n¼ 9).
Different VH genes are associated with various levels of
SHM21. The mutation rate in gliadin-speciﬁc IgA with VH3-23
was signiﬁcantly lower than the number of mutations observed in
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Figure 4 | Staining of intestinal PCs with tetramers of synthetic gluten peptides or TG2 in ﬂow cytometry. (a) Representative plots of PCs from
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‘Background SA’ represents cells stained with APC-streptavidin alone. (c) Representative plots of one subject with UCD of IgMþ PCs and IgAþ PCs from
SCSs stained with biotinylated peptides in complex with APC-conjugated strepavidin and biotinylated TG2 in complex with PE-conjugated streptavidin.
(d) Ratio of PCs stained positive with TG2 compared with synthetic gliadin peptides. IgMþ PCs and IgAþ PCs of the same sample are connected by lines.
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VH3-23 from control population (Fig. 8c). We conclude that the
low mutation rate in gliadin-speciﬁc IgA is not a result of selected
VH usage.
Discussion
We previously reported that IgA antibodies of TG2-speciﬁc PCs
found in coeliac lesions have limited SHM5. In the present
study, we have characterized gluten (gliadin)-reactive antibodies
expression cloned from IgAþ PCs isolated from small
intestinal biopsies. We found that there is also a limited
mutation rate in these antibodies, demonstrating an unexpected
common feature of the IgA antibody responses to gluten and
TG2 in CD.
The number of mutations in antibody genes relates to the type
of B-cell response elicited22. T-cell-independent B-cell responses
have no or little SHM with little restriction of VH usage as often
seen in T cell-dependent responses23. T-cell-dependent B-cell
responses that develop in germinal centers typically result in
highly mutated antibodies24. GC reactions may also happen
without the involvement of T cells, but then with low level of
SHM25. Low level of SHM is also seen in T-cell-dependent
extrafollicular responses26 and in germinal center responses of
short duration27.
For the TG2-speciﬁc IgA antibodies, the low mutation rate was
suggested to relate to enzymatic activity of B-cell receptor bound
TG2 (ref. 5) or to the early termination of autoreactive B cells in
GCs or self-antigen driving an extrafollicular response, similar to
what has been reported in other systems22,28,29. None of these
mechanisms should apply to IgA antibodies of gluten-speciﬁc
PCs, and one could therefore expect that these PCs should have
similar levels of SHM compared with control PCs. This is not
what we observed. The mutation rate in IgA of gluten-speciﬁc
PCs was low and similar to TG2-speciﬁc PCs. This suggests that
the factor(s) causing the limited SHM in IgA of TG2-speciﬁc PCs
is likely involved in both antibody responses.
The parallel ﬂuctuation of antibodies to gluten and TG2 in
response to dietary gluten10 suggests that the production of these
antibodies is regulated in a coordinated way. In keeping with this
notion, it has been suggested that gluten-speciﬁc T cells could
provide help to TG2-speciﬁc B cells by means of complexes
gluten-TG2 acting as hapten-carrier complexes30,31. This model
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Figure 5 | AlphaLISA characterization of gliadin-reactive hmAbs. (a) Antibody reactivity to constant concentration of biotinylated PLQPEQPFP in the
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would explain why the TG2 antibodies are produced upon gluten
exposure, and it would also explain why only individuals who
express HLA-DQ2 or HLA-DQ8 make these antibodies16.
Gluten-speciﬁc T cells obviously also could provide help to
gluten-speciﬁc B cells. As gluten-speciﬁc T cells preferentially
recognize deamidated gluten peptides32, B cells with surface
immunoglobulin that bind and internalize deamidated gluten
peptides would be better situated to receive T-cell help. Common
sequences of the two gliadin peptides used to isolate IgAþ PCs,
are found in or adjacent to many T-cell epitopes in gluten
proteins. The QPEXP (X¼Q, L) sequence is found in the
DQ2.5-glia-a1a/b, DQ2.5-glia-a2, DQ2.5-glia-g2, DQ2.5-glia-g3,
DQ2.5-glia-g4c/d, DQ2.5-glia-$1, DQ2.5-glia-$2, DQ2.5-
hor-1, DQ2.5-hor-2, DQ2.5-sec-1, DQ2.5-sec-2 and DQ8-glia-
g1a/b epitopes whereas the QPFP sequence is found in the
DQ2.5-glia-g4c, DQ2.5-glia-g5, DQ2.5-glia-$2, DQ2.5-hor-2,
DQ2.5-sec-2 and DQ8-glia-g1a epitopes32. The low mutation
rate in TG2- and gluten-speciﬁc PCs compared with other
intestinal PCs, suggests that a common factor distinguishing the
TG2- and gluten-speciﬁc PCs from most other gut PCs could be
implicated. Based on the model referred above, both gluten and
gluten-reactive T cells could be such common factors.
Gluten is a protein antigen, which in contrast to most antigens
of the gut has no bacterial or viral origin. Lack of strong
concomitant innate signals along with B-cell receptor triggering
could result in extrafollicular response, in accordance with a study
of the B-cell response to a T cell-dependent antigen, where
immunization without adjuvant was insufﬁcient for GC forma-
tion33. Analysis of mutation rate of antibodies to other dietary
proteins would shed light on this and should be examined in the
future.
4
2
3
Lo
g 
al
ph
aL
IS
A 
si
gn
al
 (c
ou
nts
)
33-merPLQPEQPFP
4
2
3
Lo
g 
al
ph
aL
IS
A 
si
gn
al
 (c
ou
nts
)
33-merPLQPEQPFP
4
2
3
Lo
g 
al
ph
aL
IS
A 
si
gn
al
 (c
ou
nts
)
33-merPLQPEQPFP
a
FPQPQQPEQSFP GIIQPEQPAQL PEQP QQSF PEQ ERP LQQPLSQQPEETF
Inhibiting peptide (M)
UCD1002 1B064
2
3
Lo
g 
a
lp
ha
LI
SA
 
si
gn
al
 (c
ou
nts
)
10–210–6 10–410–210–6 10–4
Inhibiting peptide (M)
UCD1143 3B024
2
3
Lo
g 
al
ph
aL
IS
A 
si
gn
al
 (c
ou
nts
)
b
Figure 6 | Epitopes of gliadin-speciﬁc hmAbs. (a) Reactivity of hmAbs to PLQPEQPFP and 33-mer. Reactivity of each hmAb is connected by line.
Antibodies are grouped according to their reactivity pattern with reactivity to only one of the two peptides (left, right) or cross-reactive with both
peptides (middle). (b) Reactivity of two representative hmAbs to constant concentration of biotinylated PLQPEQPFP in competition with four different
competitive synthetic gliadin peptides. The amino-acid sequences of competitive peptides are shown and the concentrations of competitive peptides
are depicted on x axis. Amino-acid sequences shared with the PLQPEQPFP selecting peptide are underlined.
Al
ph
aL
IS
A 
sig
na
l (c
ou
nts
)
150,000
100,000
50,000
0
UC
D-8
UC
D-7
UC
D-6
UC
D-5
UC
D-4
UC
D-3
UC
D-2
UC
D-1Ctr
-6
Ctr
-5
Ctr
-4
Ctr
-3
Ctr
-2
Ctr
-1
Figure 7 | AlphaLISA anti-PLQPEQPFP immunoglobulin inhibition assay.
Reactivity of hmAbs UCD1114 1F03 and UCD1143 3B02 to constant
concentration of biotinylated PLQPEQPFP in the presence of sera from
either UCD or control subjects (Ctr). The signal was blocked by sera from
UCD patients but not from control subjects.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5041
8 NATURE COMMUNICATIONS | 5:4041 | DOI: 10.1038/ncomms5041 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
Extrafollicular responses typically give rise to short-lived PCs
and rapid decline in serum antibodies after the immune response
in addition to low SHM34. TG2-speciﬁc PCs were rarely detected
in small intestine of CD subjects on a gluten-free diet5, and levels
of serum IgG and IgA antibodies to both gluten and TG2 typically
fall below detection level months after the patient commence a
gluten-free diet10. These clinical observations, in addition to our
observations of limited SHM in gluten-speciﬁc and TG2-speciﬁc
IgAþ PCs, argue for an extrafollicular origin of gluten and
TG2-speciﬁc antibodies in CD.
T cells inﬂuence extrafollicular development of B cells. It has
been reported that T cells located at the T-B border in lymph
nodes, phenotypically different from GC T cells, are necessary for
B-cell priming to form extrafollicular antibody responses35.
Sustained CD40 signalling during B-cell and T-cell interaction
has been demonstrated to induce a plasma cell fate rather than
GC B-cell development36, and administration of a CD40 agonistic
antibody was shown to ablate GC reaction and induced a pattern
of extrafollicular B-cell differentiation37.
Not only the quality, but also the degree of T-cell help could be
a relevant factor. Excessive numbers of follicular helper T cells as
seen in several mouse models, like the ‘san’ mutation in the RNA
binding protein Roquin38 and PD-1 deﬁciency39, drive survival of
GC B cells with a low degree of mutation and afﬁnity and cause
increased autoreactivity possibly due to a lowered threshold for
GC B-cell selection40. Interestingly, gluten-reactive T cells of CD
patients produce large amounts of interferon-g41 and in mice,
excess of interferon-g has been demonstrated to promote
accumulation of both follicular helper T cells and GC B cells
and to trigger autoimmunity42. It may thus be that TG2- and
gluten-reactive B cells in such a setting may develop in GC and
not extrafollicularly.
Characterization of the speciﬁcity of antibodies produced by
PCs reactive with gluten should give valuable insights into the
pathogenesis in CD. We thus characterized the panel of hmAbs
by AlphaLISA assays. First, we found that some antibodies are
speciﬁc to deamidated gliadin peptides and do not recognize non-
deamidated counterparts. Inevitably, gliadin-speciﬁc B cells must
have encountered deamidated gliadin. Second, we found that
gliadin-speciﬁc antibodies frequently cross-react with different
gliadin peptides. Accordingly, gliadin-speciﬁc B cells may take up
and display several different T-cell epitopes. This may be
beneﬁcial if a B cell receives help from several different T-cell
clones, as recently described43.
In addition to the limited SHM, we observed a restricted
VH/VL usage in the panel of gluten-speciﬁc antibodies. Limited
VH usage is a sign of T-cell-dependent responses23. Notably,
the same VH/VL pairings appear in different subjects. This
phenomenon is similarly seen in TG2-speciﬁc antibodies where
VH restriction is observed in different patients5. The VH usage of
TG2-speciﬁc antibodies was recently demonstrated to correlate
with epitope speciﬁcity44. We observed a similar phenomenon for
the gliadin-speciﬁc hmAbs. Antibodies speciﬁc to deamidated
variants of gluten peptides seemed to have different VH/VL usage
than antibodies with reactivity to both the deamidated and native
variants. Such VH/VL restriction is by no means unique to CD
and has been reported in antibodies speciﬁc for inﬂuenza45 and
HIV46 antigens. For HIV antibodies, there has even been reported
an allelic preference for antibody usage46. A deeper analysis may
reveal similar allelic preferences of the antibody responses to TG2
and gluten in CD. Restricted VH/VL usage and limited SHM in
antibodies as observed in CD would favour inﬂuence of VH
and/or VL polymorphisms in shaping the antibody response.
This could speak for the involvement of VH and VL genes as
susceptibility loci in CD, even though these genes have not been
indicated by recent genome-wide association studies in
humans47. Notably in mice, experiments with congenic strains
demonstrated that the antibody response to gliadin is chieﬂy
controlled by the MHC and the immunoglobulin heavy chain
loci48.
Interestingly, the hmAbs generated can be used to develop
diagnostic assays detecting patient serum antibodies reactive with
disease-relevant gluten epitopes. Given that the antibodies are
derived from PCs of the CD lesion, inhibition assays reﬂecting the
speciﬁcity of the hmAbs may potentially perform better than
assays used today. The hmAbs could potentially also be used for
detection of gluten contamination in gluten-free food.
In summary, our ﬁndings of restricted mutation rates in both
IgA antibody responses to gluten and TG2 in CD are surprising.
We suggest that a common factor important for gluten-speciﬁc
and TG2-speciﬁc B cells, possibly gluten antigen or gluten-
speciﬁc T cells, is responsible for causing low mutation rates in
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the speciﬁc IgA antibodies. There is a restricted, but different
usage of VH and VL gene segments, for recognition of gluten and
TG2 in CD. The restricted usage raises the possibility that there
might be genetic effects at the immunoglobulin loci for the
development of this disease.
Methods
Subjects. Small intestinal biopsy specimens were obtained from subjects by
esophagogastroduodenoscopy and forceps sampling from the duodenum. UCD
patients were referred to endoscopy based on clinical suspicion and positive
serologic test, and diagnosed according to the guidelines of the American
Gastroenterological Association Institute49. These subjects were still on a gluten-
containing diet at the time when biopsies were obtained, that is, when the disease
was in its active chronic stage. Non-CD controls were appointed to endoscopy,
where histopathology and serology negated CD diagnosis. The non-CD control
group consisted of seven HLA-DQ2.5þ subjects, three HLA-DQ8þ subjects and
four subjects who were not HLA-typed. All subjects have given written informed
consent. The study was approved by Regional Committees for Medical Research
Ethics South East Norway (S-97201).
Single-cell suspensions. Intestinal biopsies were collected and transported in
RPMI 1640 in 50ml tubes on ice. For preparation of SCSs18, the biopsies were
transferred to 15ml tube and resuspended in 2mM EDTA in 2% fetal calf serum
(FCS) in PBS. After 30-min rotation at 37 C, the supernatant was discarded and
the biopsies resuspended in 1mgml 1 blend collagenase (Sigma, C8051) and
50mgml 1 DNase (Sigma, DN25) in 2% FCS in Dulbecco’s PBS. The biopsies were
then incubated under constant rotation at 37 C. After 30min, the biopsies were
mechanically disrupted with a syringe equipped with a large steel needle. After
another 30min constant rotation, a smaller needle was used for the same
procedure. After 1–2 h, the single-cell suspension was ﬁltered through 40 mM ﬁlter
into 50ml tube and centrifuged at 470 g for 7min.
Human intestinal stromal cell line. Human ﬁbroblast cell lines were derived from
small intestinal biopsies as previously described50. Biopsies were transferred to
ﬂat-bottomed six-well plates and gently disrupted with a scalpel for 15–30 s. The
biopsies were cultured in 1% penicillin/streptomycin in 10% FCS in RPMI 1640
(culture medium) at 37 C in 5% CO2. Medium was changed every second week.
After 5–10 weeks, a dense layer of cells attached to the bottom was detectable in the
wells. These cells were detached with 0.05% trypsin-EDTA (Gibco, 25300–054) and
transferred to 25ml culture ﬂasks. Culture medium was changed regularly. In these
ﬂasks, the cell lines typically survived for 6–9 months. One of these cell lines, F1100
from subject UCD1100, was used in most of the experiments.
In vitro co-culture of SCSs and ﬁbroblasts. First, ﬁbroblasts were detached from
25ml culture ﬂasks and transferred to plates with ﬂat-bottomed wells. After 1 week,
cells from SCSs were seeded on conﬂuent layer of ﬁbroblasts. Fibroblasts and SCSs
were incubated in culture medium at 37 C in 5% CO2. Different plate formats
were suited to different experimental settings; 24-well plates were used for BrdU
assays and estimation of total IgA production and 384 well plates were used of
single PC cultures.
Extraction and preparation of gliadin proteins. Gliadin, the alcohol soluble
component of gluten, was extracted from wheat ﬂour. Wheat ﬂour (Møllerens
550001) 50 g was dissolved in 150ml butanol, vortex mixed and centrifuged at
163 g for 5min. The butanol was decanted and the procedure repeated. The wheat
ﬂour pellet was dissolved in 350ml 70% ethanol and incubated at RT overnight
under constant stir mixing. Next day, the solution was centrifuged at 650 g for
5min, and the supernatant was mixed with 1.5M NaCl in ratio 1:2 and incubated
at 4 C for 4 h to precipitate the gliadin proteins. After centrifugation at 25,000 g for
20min, the supernatant was decanted and the gliadin pellet dissolved in 40ml 8M
urea in 0.01M ammonium bicarbonate. This solution was diluted 1:4 to give a ﬁnal
urea concentration of 2M and incubated with 12–24mg chymotrypsin (CT)
overnight at 37 C under constant stir mixing. Next day, chymotrypsin was heat
inactivated at 98 C for 5min, and the solution was dialyzed (Spectra/Por
Membrane MWCO 1,000) overnight and dried in speed vacuum concentrator. The
digested gliadin was dissolved and incubated in acetic acid pH 1.8 at 95 C for 1 h
to introduce Q to E conversion (deamidation). The ﬁnal product, heat/acid-treated
chymotrypsin-digested gliadin (CT-gliadin for short), was diluted in distilled H2O
and freeze dried before further usage.
ELISA supernatant IgA reactive with CT-gliadin. ELISA plates (96 well Nunc
436014) were coated with 75 ml per well of CT-gliadin 40 mgml 1 in carbonate
buffer 0.05M pH 9.6 overnight at 4 C, washed and subsequently blocked with
0.5% BSA in PBS and incubated with supernatant from single PC cultures. Anti-
human IgA-alkaline phosphatase (Sigma, A9669) 1:3,000 was used as secondary
antibody. Anti-human IgG-alkaline phosphatase (Southern Biotech, 2040-04) at
concentration 1:4,000 was used when testing gliadin-reactive hmAbs. Plates
were developed for B15min with phosphatase substrate (Sigma-Aldrich) and
absorbance was measured at 405 nm.
Isolation of PCs after in vitro culture. Cells from culture wells were transferred to
PCR plate and centrifuged at 3,750 g for 5min. Supernatant was decanted, and
RNAse-inhibiting RT–PCR catch buffer17 was added, 10ml per well. PCR plate was
sealed and stored at -70 C until single-cell PCR preparation.
Staining antigen-speciﬁc PCs from SCSs. Two different biotinylated
synthetic gliadin peptides were used to stain gliadin-speciﬁc PCs from SCSs.
Biotin-GSGSGS-PLQPEQPFP and biotin-GSGSGS-LQLQPFPQPELPYPQPELPY
PQPELPYPQPQPF were produced by GL Biochem (Shanghai). TG2 was expressed
in Sf9 insect cells by Phadia and linked to biotin with Sulfo-NHS-LC-biotin
(Pierce) as per the manufacturer’s protocol.
The synthetic peptides were incubated on ice with APC-labelled streptavidin
(PhycoLink, PJ27S) and biotinylated TG2 incubated with PE-labelled streptavidin
(Invitrogen, S866) at 4:1 molar ratio, in the dark for 1 h. The ﬁnal tetramer
concentration for staining intestinal PCs was 40 nM in staining buffer containing
2% FCS in PBS. PE CD138 1:40 (eBioscience, DL-101), PE-Cy7 CD27 1:50
(eBioscience, LG.7F9), Paciﬁc Blue CD19 1:100 (BioLegend, HIB19), PerCP CD3
1:40 (BD Biosciences, SK7), PerCP CD14 1:40 (BD Biosciences, MfP9), FITC goat
anti-human IgA 1:800 (Southern Biotech, 2050-02) were used for staining of SCS.
Propidium iodide for exclusion of dead cells was added just before analysis. Three
different ﬂow cytometer instruments were used: Facs Aria, LSRII and Fortessa. The
plots in this manuscript (Figs 1 and 3, Supplementary Figs 1 and 2) are from LSRII.
PCs appeared as one homogeneous population of large, CD4 and CD14 events,
coexpressing CD138 and CD27, and were previously identiﬁed as antibody
producing cells18. CD27 stained with higher intensity and gave a more deﬁned
population than CD138. Thus, PCs were deﬁned as large, viable,
CD27þCD3CD14 events.
Cloning and expression of hmAbs. The variable regions of the heavy and light
chain antibody genes of isolated PCs were ampliﬁed by RT–PCR and nested PCR
using the same primers as previously described17, cloned into expression vectors
and transfected into a human cell line as IgG1 according to previously established
protocol17.
AlphaLISA screening of hmAbs for reactivity to gluten peptides. AlphaLISA
Acceptor beads (Perkin Elmer, 6772001) were coupled with polyclonal rabbit anti-
human IgG (Dako A0423) and stored at a concentration of 2.5mgml 1 according
to the manufacturer’s instructions (as gliadin-speciﬁc hmAbs were produced in
human IgG1 format). Anti-IgG AlphaLISA donor bead solution (1:400) and glia-
din-speciﬁc hmAbs 1 mgml 1 in AlphaLISA immunoassay buffer (Perkin Elmer,
AL000C) were incubated for 1 h at 4 C in the dark. After incubation, 15 ml were
transferred to each well in 384 well plates and mixed with 5 ml analyte. The plates
were incubated for 1 h at RT in the dark. AlphaScreen streptavidin donor bead
solution (Perkin Elmer, 6760002B) was diluted 1:200 in AlphaLISA Immunoassay
buffer, and 15ml were added per well before incubation at RT in the dark for
30min. The different peptides used in the analyte were the following: biotin-
GSGSGS-PLQPEQPFP, PLQPQQPFP, PLQPEQPFP, GIIQPEQPAQL,
LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF, FPQPQQPEQSFP,
PEQPQQSFPEQERP, LQLQPFPQPELPYPQPELPYPQPELPYPQPQPF,
LQQPLSQQPEETF and biotin-GSGSGS-LQLQPFPQPELPYPQPELPYPQPELPY
PQPQPF were purchased from GL Biochem, Research Genetics, Neosystems or
obtained from Burkhard Fleckenstein.
AlphaLISA Acceptor beads were also coupled to equal amounts of the two
gliadin-speciﬁc hmAbs UCD1114 1F03 and UCD1143 3B02 and stored at
concentration 2.5mgml 1. These beads were used to detect biotin-GSGSGS-
PLQPEQPFP in the presence of serum (Fig. 7). First, 5 ml biotin-GSGSGS-
PLQPEQPFP was incubated with 10 ml serum at RT for 30min. Then, 30 ml of
mixture of AlphaLISA acceptor bead solution (1:600) and Alphascreen donor bead
solution (1:300) in AlphaLISA immunoassay buffer, was added per well. The plate
was read after second incubation for 45min at RT in the dark. In pilot experiments,
several gliadin-speciﬁc hmAbs were tested and gave similar results. The hmAbs
UCD1114 1F03 and UCD1143 3B02 were chosen for the ﬁnal experiments as
they were among the commonly used VH/VL pairs VH3-23/VL4-69 and VH3-15/
VK4-1, respectively.
AlphaLISA screening of hmAbs for gliadin speciﬁcity. Anti-IgG AlphaLISA
donor bead solution (1:400) and gliadin-speciﬁc hmAbs 1 mgml 1 in AlphaLISA
immunoassay buffer were incubated in 1.5ml tube for 1 h at RT in the dark before
15 ml was transferred to each well in 384 well plate. Then 5 ml analyte was added per
well, and the plate subsequently incubated for 30min at RT in the dark. The
analyte consisted of ﬁxed concentration of 40 nM biotin-GSGSGS-PLQPEQPFP
and titrations of either CT-gliadin, lysate of EBV-transfected B cells or a mixture of
LPS (Sigma L-4391), CpG, recombinant TG2 (Phadia) and recombinant Jo-1
antigen (Phadia). After 45min incubation at RT in the dark, AlphaScreen
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streptavidin donor bead solution was diluted 1:200 in AlphaLISA Immunoassay
buffer and 15 ml added per well. The plate was read after 30min incubation at RT in
the dark.
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